BioVaxys Technology (BioVaxys Technology) EBITDA Margin % : 0.00% (As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioVaxys Technology's EBITDA for the three months ended in Jul. 2023 was $-0.43 Mil. BioVaxys Technology's Revenue for the three months ended in Jul. 2023 was $0.00 Mil. Therefore, BioVaxys Technology's EBITDA margin for the quarter that ended in Jul. 2023 was 0.00%.

BioVaxys Technology EBITDA Margin % Historical Data

The historical data trend for BioVaxys Technology's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology EBITDA Margin % Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

EBITDA Margin %

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioVaxys Technology's EBITDA Margin %

For the Biotechnology subindustry, BioVaxys Technology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's EBITDA Margin % falls into.

BioVaxys Technology EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

BioVaxys Technology's EBITDA Margin % for the fiscal year that ended in Oct. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Oct. 2022 )	/	Revenue (A: Oct. 2022 )
	=	-2.982	/	0
	=	%

BioVaxys Technology's EBITDA Margin % for the quarter that ended in Jul. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jul. 2023 )	/	Revenue (Q: Jul. 2023 )
	=	-0.425	/	0
	=	%

BioVaxys Technology (OTCPK:BVAXF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

BioVaxys Technology EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.